San Diego, CA -- (SBWIRE) -- 05/22/2018 -- An investigation on behalf of investors of Akcea Therapeutics, Inc. (NASDAQ: AKCA) shares over potential securities laws violations by Akcea Therapeutics, Inc.

Investors in shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Akcea Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Cambridge, MA based Akcea Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally.

Shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) reached $33.98 per share in March 2018.

On May 8, 2018, the U.S. Food and Drug Administration ("FDA") published briefing documents in advance of a May 10, 2018 advisory panel meeting regarding Akcea's volanesorsen product. In the briefing documents, the FDA noted that significant portions of patients treated with volanesorsen had experienced steep reductions in their blood platelet counts.

Shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) declined to $17.74 per share on May 8, 2018.

Those who purchased shares of Akcea Therapeutics, Inc. (NASDAQ: AKCA) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com